NEWS

August 16, 2024
Gilead Must Commit to Immediately and Broadly License Lenacapavir to the MPP and ViiV Must Take Steps to Expand and Unshroud its MPP License on Dolutegravir

February 29, 2024
Gilead’s ESG Awards Are Worthless. What About Drug Prices?

January 16, 2024
Federal court rejects drugmaker’s efforts to end lawsuit claiming they delayed more effective HIV treatment for more expensive, less effective drug

October 9, 2023
‘Responsible Investors: Dump Gilead’ Says AHF Ad

October 4, 2023
HIV drugmaker will pay $246 million to settle suit over generic meds delay

October 4, 2023
How a Drugmaker Profited by Slow-Walking a Promising H.I.V. Therapy

October 4, 2023
Gilead must stand trial over defective HIV drug claims

December 12, 2022
AHF Protest: Gilead Destroys Rx Safety Net for its Own Profit

December 12, 2022
AHF Protests Gilead over Drug Pricing @ Morgan Stanley Conf. in NYC

December 12, 2022